Aktis Oncology, Inc. (AKTS) Stock Price & Analysis
Aktis Oncology, Inc. (AKTS) rose 0.05% to USD 18.98 as of June 10, 2026 at 02:22 UTC, according to Nexqual real-time market data.
AKTS last closed at USD 18.97; the session ranged USD 18.36–19.65 on volume of 129,698 shares. Market capitalization is $1.05B, with a 52-week range of USD 14.72–29.16 (NMS). Source: Nexqual, June 10, 2026 at 02:22 UTC.
Key Statistics (as of June 10, 2026 at 02:22 UTC)
| Price | USD 18.98 |
|---|---|
| Change | ▲ 0.05% (up) |
| Previous Close | USD 18.97 |
| Open | USD 19.25 |
| Day Range | USD 18.36 – 19.65 |
| 52-Week Range | USD 14.72 – 29.16 |
| Volume | 129,698 shares |
| Market Cap | $1.05B |
| Exchange | NMS |
Technical Analysis (AKTS)
Nexqual's technical model rates AKTS "SELL" based on 1 bullish and 4 bearish signals across 104 daily candles, as of June 10, 2026 at 02:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.13 (neutral) |
| vs SMA50 | Below (USD 19.07) |
| MACD | 0.02 (positive) |
Analyst Ratings (AKTS)
Wall Street analysts rate AKTS "Strong Buy" based on 5 analysts, with a mean price target of USD 32.65 (range USD 30–35), per Nexqual as of June 10, 2026 at 02:22 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 32.65 |
| High Target | USD 35 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (AKTS)
| Next Earnings Date | 2026-05-11 |
|---|---|
| EPS Estimate | USD -0.45 |
| Revenue Estimate | $3.13M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.38 vs est -0.33 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
Financials & Fundamentals (AKTS)
| Total Revenue | $8.28M |
|---|---|
| Revenue Growth (YoY) | +123.00% |
| Gross Margin | +0.00% |
| Operating Margin | -703.63% |
| Profit Margin | +0.00% |
| Debt / Equity | 2.29 |
| Current Ratio | 19.49 |
| Total Cash | $538.48M |
| Total Debt | $11.58M |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
Financial Health Score (AKTS)
Nexqual rates Aktis Oncology, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:22 UTC.
| Growth | Strong — Revenue +123% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $538M cash vs $12M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$71M |
| Efficiency | Mixed — No data |
Ownership (AKTS)
| Insider Ownership | +14.14% |
|---|---|
| Institutional Ownership | +74.19% |
| Shares Outstanding | 53.40M |
| Float | 28.15M |
| Short % of Float | +16.85% |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
Leadership (AKTS)
Aktis Oncology, Inc. is led by Matthew Roden, President, CEO & Director, per Nexqual as of June 10, 2026 at 02:22 UTC.
| President, CEO & Director | Matthew Roden |
|---|---|
| Co-Founder & Chairman | Todd Foley (age 53) |
| Chief Scientific Officer | Paul L. Feldman (age 63) |
| Chief Financial Officer | Kyle D. Kuvalanka (age 57) |
| Chief Operating Officer | Shulamit Ron-Bigger (age 44) |
Major Backers & Investors (AKTS)
Notable institutional backers of Aktis Oncology, Inc. include MPM Bioimpact LLC, EcoR1 Capital, LLC, T. Rowe Price, according to Nexqual as of June 10, 2026 at 02:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MPM Bioimpact LLC | 9.06% |
| EcoR1 Capital, LLC | 9.03% |
| T. Rowe Price | 6.35% |
| Blue Owl Capital Holdings LP | 5.92% |
| Wellington Management | 4.34% |
| Price (T.Rowe) Associates Inc | 3.53% |
| RTW Investments LP | 2.98% |
| RA Capital Management, L.P. | 2.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.33% |
| Vanguard Group | 3.98% |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
From Aktis Oncology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
- The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
- It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPRO | Spero Therapeutics, Inc. | USD 2.57 | ▼ 8.87% |
| DTIL | Precision BioSciences, Inc. | USD 6.86 | ▲ 5.54% |
| AIRG | Airgain, Inc. | USD 6.84 | ▲ 0.74% |
| INSG | Inseego Corp. | USD 10.45 | ▼ 8.49% |
| ATOM | Atomera Incorporated | USD 8.05 | ▼ 2.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:22 UTC. This page is informational and not investment advice.